IMMUNOLOGY TEXTBOOK - Mercury Podillia 2013

CONCEPT OF IMMUNE STATUS AND IMMUNOGRAM: INTERPRETATION OF IMMUNOGRAMS

Guidelines to Follow When Interpreting Immunograms

1. A comprehensive clinical analysis of an immunogram can only be performed in conjunction with an Assessment of the patient's Clinical presentation and medical history. Drawing clinical Conclusions based solely on an immunogram is unacceptable, as identical shifts in immunogram parameters can be observed across various pathologies.

2. A comprehensive analysis of an immunogram is far more informative than evaluating each parameter in isolation. The same parameter shift during different phases of an acute inflammatory process may be interpreted as either a favorable or unfavorable sign.

3. Only consistently pronounced shifts in parameters provide meaningful diagnostic information in an immunogram.

4. Serial (longitudinal) analysis of immunograms is more informative both diagnostically and prognostically than a single isolated immunogram. In the vast majority of cases, analyzing a single immunogram offers only general orientation rather than definitive DIAGNOSTIC AND PROGNOSTIC conclusions. Therefore, accurate Diagnosis and prognosis require at least two immunograms evaluated dynamically over the course of the process.

5. In the final Conclusion, formulated on The basis of the clinical picture and immunogram analysis, the clinical diagnosis must take precedence. Clinical data play a paramount role, while the immunogram provides essential diagnostic and prognostic insights. The absence of immunogram shifts in the presence of a clinical pathology warrants a functional investigation of specific immune system compartments.

6. Individual baseline norms for a given patient are critical for the diagnostic and prognostic evaluation of an immunogram, particularly when considering age, concomitant and chronic conditions, environmental or occupational hazards, and pharmacotherapy.

7. The ratios of T-Cell populations and subpopulations carry significantly greater practical significance than their absolute values.

8. A discrepancy between immunogram shifts and the Clinical presentation of the disease indicates an unfavorable disease trajectory. The higher the antigenicity of a foreign agent and the broader its site of invasion, the more pronounced the inflammatory response will be. Consequently, larger shifts in immunograms should be expected, reflecting an adequate immune system response.

9. The absence of expected Changes in the leukogram and immunogram is an unfavorable sign indicating an inadequate Immune Response. A lack of immunogram shifts in the presence of an active inflammatory process should be interpreted as an atypical immune reaction and serves as an ominous prognostic indicator. Timely recognition of such discrepancies by the clinician is a primary objective of clinical immunology.

Thanks to immunological assays, clinical immunologists can evaluate the function of major immune pathways, assess a patient's immune status, judiciously prescribe Immunomodulatory therapy, and monitor Treatment efficacy through serial immunological follow-up. Reference ranges for immune status parameters are provided in Table 29.

Class="center">Table 29. Parameters of Immune Status

Parameter Name

Unit

Reference Range

Parameters of Phagocytic and Microbicidal Activity

Leukocyte count

109 /л

4,4-11,0

Neutrophil count

%

40-70

Monocyte count

%

3-8

Eosinophil count

%

1-5

Phagocytic number (PN)

Абс. число

5-10

Phagocytic percentage (PP)

%

65-95

Index of Digestion (ID)

Од

>1,0

Active phagocyte count (APC)

109 /л

1,6-5,0

Activated NBT test

%

40-80

Spontaneous NBT test

%

до 10

Lysosomal-cationic test (LCT)

Од

1,2-1,8

Granulocyte oxidative METABOLISM test

Од

141-212

Activated chemiluminescence of phagocytes (Burst test with E. coli and PMA)

% Од

95-100

600-1800

Spontaneous chemiluminescence of phagocytes

%

1-20

Natural killer cell count (CD16)

%

6-26

NK cell count (CD56)

%

9-19

Activated granulocyte count (CD16)

%

65-95

Apoptotic neutrophil count (CD95)

%

5-10

Apoptotic monocyte count (CD95)

%

5-7

Interleukin-1 level

пг/мл

30-50

Interleukin-6 level

нг/мл

30-500

Colony-stimulating factor level

пг/мл

0-4,0

TNF level

нг/мл

0-87

Parameters of Humoral Non-Specific Resistance

Serum Complement component C3 level

г/л

0,9-1,8

Serum complement component C4 level

г/л

0,1-0,4

Serum total complement titer

Од. СН50

35-60

Serum C-reactive protein level

мг/л

<5

Blood Lysozyme level

мкг/мл

7-14

Circulating immune complexes (CIC) level

Од

30-90

CIC level with C1q complement

мг/мл

0-40

Parameters of Humoral Immunity

Serum immunoglobulin A level

г/л

0,7-4,0

Serum immunoglobulin M level

г/л

0,4-2,3

Serum immunoglobulin G level

г/л

7,0-16,0

Total immunoglobulin E level

МО/мл

0-100

Specific antibody level (indicated upon pathogen identification to assess immune response magnitude)



Tumor marker level (indicated upon suspicion of malignancy)

-

-

Serum antistreptolysin-O level

МО/мл

<200,0

Serum rheumatoid factor level

МО/мл

<14,0

Type 2 T-helper count (CD4/29)

%

1-3

Interleukin-4 level

-

-

Interleukin-8 level

нг/мл

50-500

B-lymphocyte count (CD20)

%

8-19

Absolute B-lymphocyte count (CD20)

109 /л

0,19-0,38

Activated B-lymphocyte count (CD20/69)

%

6-12

Activated B-lymphocyte count (CD23)

%

6-12

B-lymphocyte count (CD5+)

%

-

IgA+ B-lymphocyte count

%

1-3

IgM+ B-lymphocyte count

%

3-10

IgG+ B-lymphocyte count

%

2-6

IgD+ B-lymphocyte count

%

-

Parameters of Cell-Mediated Immunity

Lymphocyte count

%

25-39

T-lymphocyte count (CD3)

%

50-80

Absolute T-lymphocyte count (CD3)

109 /л

1,1-1,7

T-helper count (CD4)

%

36-55

Absolute T-helper count (CD4)

109 /л

0,4-1,1

T-suppressor count (CD8)

%

20-33

Absolute T-suppressor count (CD8)

109 /л

0,3-0,7

Immunoregulatory index (Th/Ts)

Од

1,5-2,5

T-lymphocyte differentiation index

Од

0,9-1,0

Type 1 T-helper count (CD45RA)

%

32-45

Memory T-lymphocyte count (CD45RO)

%

-

Activated T-lymphocyte count (HLA-DR)

%

12-20

T-lymphocyte count with IL-2 receptors (CD25)

%

13-24

Null (undifferentiated) lymphocyte count

%

5-27

Spontaneous lymphocyte blastogenesis (LST)

%

до 10

Phytohemagglutinin (PHA)-stimulated lymphocyte blastogenesis (LST)

%

36-54

Activated T-helper count (CD4/69)

%

40-70

Activated T-suppressor count (CD8/69)

%

40-70

Apoptotic lymphocyte count (CD95)

%

5-10

T-lymphocyte activity in leukocyte migration inhibition test (LMIT) with PHA

%

20-80

Interleukin-2 receptor level

нг/мл

700-5000

Interleukin-2 level

Од/мл

0-0,5

Interleukin-12 level

пг/мл

30-100

IFN-γ level

пг/мл

30-50

Lymphocyte sensitivity to immunomodulators

%

20-80



Last update: 13/08/2026

Editorial and Educational Adaptation: This material has been compiled based on the primary/original source text. The project team performed an editorial review, corrected technical inaccuracies, structured sections, and adapted the content for an educational format.

What was processed:

  • elimination of formatting defects (OCR errors, structural breaks, corrupted characters);
  • editorial organization of content;
  • standardization of terminology in accordance with academic sources;
  • verification of factual statements against the original source text.

All mentions of the author, publication year, and origin of the primary text have been preserved in accordance with the source.